GlassScriptPhysician profile
Alexander W Brown
NPI 1083750962
$1,855.95
in general payments reported to CMS, 2019-2025
30 companies · $379 in 2025
The $379 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2021: $36.79 · 2022: $471 · 2023: $364 · 2024: $295 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.93 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $342.03 | 2022-2025 | Reblozyl, Pomalyst, Pomalyst |
| Novartis Pharmaceuticals Corporation | $240.32 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $183.52 | 2019-2025 | Opdivo |
| Pfizer INC. | $115.77 | 2019-2024 | |
| Puma Biotechnology, INC. | $114.58 | 2019 | |
| Janssen Scientific Affairs, LLC | $101.97 | 2019 | |
| Springworks Therapeutics, INC. | $86.04 | 2024-2025 | Ogsiveo |
| Amgen INC. | $76.49 | 2022 | |
| Abbvie INC. | $58.33 | 2024-2025 | |
| Incyte Corporation | $48.73 | 2022-2025 | Jakafi |
| Janssen Biotech, INC. | $46.30 | 2022-2025 | Rybrevant, Erleada, Balversa |
| Genzyme Corporation | $45.06 | 2023 | |
| Merck Sharp & Dohme LLC | $38.56 | 2019-2022 | |
| Genentech USA, INC. | $38.33 | 2022-2025 | Polivy |
| Regeneron Healthcare Solutions, INC. | $36.79 | 2024-2025 | Libtayo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $31.85 | 2025 | Brukinsa |
| Eisai INC. | $29.42 | 2021-2025 | |
| Seagen INC. | $26.22 | 2022 | |
| Sirtex Medical INC | $26.03 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.37 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.23 | 2025 | Imfinzi |
| Beigene USA, INC. | $18.53 | 2024 | Brukinsa |
| Octapharma USA, INC. | $17.26 | 2023 | Panzyga |
| Epizyme, INC. | $16.47 | 2022 | |
| Daiichi Sankyo INC. | $14.94 | 2022 | |
| Adaptive Biotechnologies Corporation | $14.46 | 2022 | |
| Caris Mpi, INC. | $13.71 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $12.16 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Clovis Oncology, INC. | $10.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.